Urinary glycoproteomic profiling of non-muscle invasive and muscle invasive bladder carcinoma patients reveals distinct N-glycosylation pattern of CD44, MGAM, and GINM1
PDF | Full Text | Supplementary Files | How to cite
Metrics: PDF 1001 views | Full Text 1948 views | ?
Gajanan Sathe1,2,6,*, Irene A. George1,2,*, Barnali Deb1,2,#, Ankit P. Jain1,#, Krishna Patel1,3, Brusabhanu Nayak4, Subhradip Karmakar5, Amlesh Seth4, Akhilesh Pandey1,2,6,7 and Prashant Kumar1,2
1 Institute of Bioinformatics, International Technology Park, Bangalore 560066, India
2 Manipal Academy of Higher Education (MAHE), Manipal 576104, India
3 School of Biotechnology, Amrita Vishwa Vidyapeetham, Kollam 690525, India
4 Department of Urology, All India Institute of Medical Sciences, New Delhi 110070, India
5 Department of Biochemistry, All India Institute of Medical Sciences, New Delhi 110070, India
6 Center for Molecular Medicine, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore 560029, India
7 Department of Laboratory Medicine and Pathology, Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA
* These authors contributed equally to this work and share the first authorship
# These authors contributed equally to this work and share the second authorship
|Prashant Kumar,||email:||[email protected]|
Keywords: urothelial carcinoma; N-linked glycoproteomics; urine proteomics; NMIBC; MIBC
Received: June 01, 2020 Accepted: July 14, 2020 Published: August 25, 2020
Clinical management of bladder carcinomas (BC) remains a major challenge and demands comprehensive multi-omics analysis for better stratification of the disease. Identification of patients on risk requires identification of signatures predicting prognosis risk of the patients. Understanding the molecular alterations associated with the disease onset and progression could improve the routinely used diagnostic and therapy procedures. In this study, we investigated the aberrant changes in N-glycosylation pattern of proteins associated with tumorigenesis as well as disease progression in bladder cancer. We integrated and compared global N-glycoproteomic and proteomic profile of urine samples from bladder cancer patients at different clinicopathological stages (non-muscle invasive and muscle-invasive patients [n = 5 and 4 in each cohort]) with healthy subjects (n = 5) using SPEG method. We identified 635 N-glycopeptides corresponding to 381 proteins and 543 N-glycopeptides corresponding to 326 proteins in NMIBC and MIBC patients respectively. Moreover, we identified altered glycosylation in 41 NMIBC and 21 MIBC proteins without any significant change in protein abundance levels. In concordance with the previously published bladder cancer cell line N-glycoproteomic data, we also observed dysregulated glycosylation in ECM related proteins. Further, we identified distinct N-glycosylation pattern of CD44, MGAM, and GINM1 between NMIBC and MIBC patients, which may be associated with disease progression in bladder cancer. These aberrant protein glycosylation events would provide a novel approach for bladder carcinoma diagnosis and further define novel mechanisms of tumor initiation and progression.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.